In its latest acquisition to strengthen its orphan drug portfolio, Horizon Therapeutics has agreed to acquire Viela Bio, a clinical-stage biotechnology company focused on the development and commercialisation of therapeutics for autoimmune and severe inflammatory diseases. The acquisition, which values Viela at US$3.05 B, gives Horizon access to Uplizna® (inebilizumab) as well as three mid-stage candidates. The buyout comes less than a year after Horizon purchased Curzion Pharmaceuticals for its Phase II autoimmune disease candidate CZN001 (now known as HZN-825).